BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children

PURPOSE: To assess the efficacy, pharmacokinetics, and safety of a new, highly purified 10% IVIg (BT595, Yimmugo(®)) administered in children with PID. METHODS: This was an open-label, prospective, uncontrolled, multicenter Phase III pivotal trial. Among the 67 subjects in the trial were 18 pediatri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kriván, Gergely, Borte, Michael, Soler-Palacin, Pere, Church, Joseph A., Csurke, Ildiko, Harris, James B., Lieberman, Jay A., Melamed, Isaac R., Moy, James N., Simon, Reka, Aigner, Silke, Lentze, Stephan, Staiger, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958146/
https://www.ncbi.nlm.nih.gov/pubmed/36383294
http://dx.doi.org/10.1007/s10875-022-01397-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958146/
https://www.ncbi.nlm.nih.gov/pubmed/36383294
http://dx.doi.org/10.1007/s10875-022-01397-0

Ejemplares similares